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Abstract 
 
The R563Q mutation of the -subunit of the epithelial sodium channel gene 
associated with hypertensive disease and related complications in pregnancy. 
     
Viljoen JE, Theron GB, Hillerman R. 
 
Introduction:   Hypertensive disease is one of the cardinal causes of maternal 
morbidity and mortality in South Africa. According to the National Confidential 
Enquiry into Maternal Deaths (NCEMD) report for 2005-2007, the “big five” causes of 
maternal death have remained the same as in the previous triennium, with 
hypertensive disease in second place, being the causative factor in 15.7% of cases.1 
Women under 20 years of age were at greater risk of dying due to complications of 
hypertension. In this light, the early identification and treatment of hypertensive 
disease remains important priorities in improving maternal care. Various serum 
markers have been studied to identify women at risk of pre-eclampsia, including 
biological markers and genetic factors.2 It is also well known that chronic 
hypertension is one of the major predisposing factors to the development pre-
eclampsia.2 A continued search for a genetic screening test to assist in early 
diagnosis could facilitate a reduction of maternal morbidity and mortality. 
 
Aims:  The aim of this project is to determine the prevalence of the R563Q mutation 
of the -subunit of the epithelial sodium channel ( -ENaC) gene in a cohort of 
primigravid women with hypertensive disease in pregnancy and to compare 
pregnancy outcomes in this group of hypertensive patients to those not identified to 
be carriers of the mutation.  
 
Methodology:  A retrospectively collected study cohort of patients with early onset 
pre-eclampsia, obtained from pooled samples and data from the GAP study (Genetic 
Aspects of Pre-eclampsia, project number C99/025), was used. The planned sample 
size was 200, with 200 controls who were ethnic-matched, normotensive women. 
Exclusion criteria were gestation 34 weeks, multiple pregnancy, known underlying 
collagen vascular disease and type I Diabetes Mellitus. Outcome criteria: The 
pregnancy outcomes were analysed with respect to the degree of hypertensive 
disease and related complications (maternal, placental and neonatal). 
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Results:  Blood samples form 104 patients and 80 control samples were analysed. 
Pre-eclamptic patients were significantly younger than controls (p<0.0001). The 
presence of the mutation was not significantly increased in the pre-eclamptic group 
(p=0.33). The mutation bearers did not exhibit a significant tendency towards a 
specific degree of pre-eclampsia (p=0.51). There were no significant differences in 
the other studied maternal or fetal outcome measures. A composite outcome (the 
presence of 1 adverse outcome compared to no adverse outcome) was created 
which did not differ between the mutation positive and negative pre-eclamptic 
patients. Data of the index study was combined with the data form a prior relevant 
study9 and combined odds ratios were calculated. The increased mutation frequency 
amongst pre-eclamptics compared to healthy controls then remains significant, OR 
2.57(95%CI 1.23-5.36). 
 
 
Conclusion:  In this study the R563Q mutation of the ß-subunit of the epithelial 
sodium channel gene was not linked to pre-eclampsia. No significant negative 
correlation could be established between the presence of the R563Q mutation and 
the outcomes of pre-eclampsia. Further research aimed at chronic hypertensive 
patients in pregnancy and unstable pre-eclampsia in larger study groups could shed 
more light on the relation between the mutation and the pre-eclamptic phenotype. 
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Opsomming 
 
Die verband tussen die R563Q mutasie van die -subeenheid van die epiteliële 
natriumkanaal geen met hipertensiewe siekte en verwante komplikasies in 
swangerskap. 
     
Viljoen JE, Theron GB, Hillerman R. 
 
Inleiding: Hipertensie-verwante siektes is een van die hoof oorsake van moederlike 
morbiditeit en mortaliteit in Suid-Afrika. Volgens die Nasionale Vertroulike Ondersoek 
insake Moederlike Sterftes (NCEMD) verslag vir 2005-2007, is die “groot vyf” 
oorsake van moedersterftes dieselfe as in die vorige triënnium, met hipertensie-
verwante siektes in tweede plek, as die oorsaak van 15.7 % van die sterfgevalle. 1  
Vroue jonger as 20 jaar het ‘n groter risiko om te sterf aan die komplikasies van 
hipertensie-verwante siektes. In die lig hiervan is die vroeë identifikasie en 
behandeling van hipertensie-verwante siektes ‘n priorteit in die verbetering van 
moedersorg. Verskeie serum merkers is al bestudeer met die hoop om vroue met 
verhoogde risiko vir die ontwikkelling van pre-eklampsie te identifiseer, wat 
biologiese merkers en genetiese faktore insluit. 2 Dit is ook welbekend dat chroniese 
hipertensie een van die hoof predisponerende faktore is vir die ontwilkkeling van pre-
eklampsie.2 ‘n Voortgesette soektog na ‘n genetiese siftingstoets wat kan bydra tot 
vroeë identifisering, sou moederlike morbiditeit en mortaliteit kon verminder. 
 
Doelwittle:  Die doelwit van hierdie projek is om die prevalensie van die R563Q 
mutasie van die -subeenheid van die epiteliële natrium kanaal ( -ENaC) geen te 
bepaal in ‘n kohort primigravida vroue met hipertensie-verwante siekte in 
swangerskap en om die swangerskapsuitkomste van hierdie groep te vergelyk met 
pasiente wat nie draers van die mutasie is nie. 
 
Metodologie:  
‘n Retrospektief versamelde studie kohort met vroeë aankoms pre-eklampsie, verkry 
van die monsterbank en data van die GAP studie (Genetic Aspects of Pre-eclampsia, 
projek nommer C99/025) is gebruik. Die beplande steekproef grootte was 200, met 
200 kontroles, wat etnies- en ouderdomvergelykbare normotensiewe vroue was. 
Uitsluitingskriteria was gestasie 34 weke, onderliggende bindweefselsiekte en tipe I 
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Diabetes Mellitus. Uitkomskriteria: Swangerskap uitkomste was geanaliseer met 
betrekking tot die graad van hipertensiewe siekte en verwante kompliksies 
(moederlik, plasentaal en neonataal). 
 
Resultate: Bloed monsters van 104 pasiënte en 80 kontroles is ontleed. Pre-
eklampsie pasiënte was betekenisvol jonger as kontroles (p<0.0001). Die 
teenwoordigheid van die mutasie was nie betekenisvol verhoog in die pre-eklampsie 
groep nie (p=0.33). Die mutasie-draers het nie ‘n geneigdheid tot ‘n spesifieke graad 
van pre-eklampsie getoon nie (p=0.51). Daar was geen betekenisvolle verskille 
tussen die ander moederlike of fetale uitkomste wat bestudeer is nie. ‘n 
Gesamentlike uitkoms (teenwoordigheid van 1 swak uitkoms vergeleke met geen 
swak uitkoms) is geskep; daar was geen verskil tussen die mutasie-positief en 
negatiewe pasiënte met pre-eklampsie nie. Data van die indeks studie en relevante 
data uit ‘n vorige studie9 is saamgevoeg en die gesamentlike kansverhouding is 
bereken. Die verhoogde mutasie frekwensie onder pasiënte met pre-eklampsie 
vergeleke met gesonde kontroles was betekenisvol, KV 2.57(95%VI 1.23 - 5.36). 
 
 
Gevolgtrekking: In hierdie projek was daar nie ‘n verband tussen die R563Q 
mutasie van die -subeenheid van die epiteliële natrium kanaal ( -ENaC) geen en 
pre-eklampsie nie. Geen betekenisvolle negatiewe korrelasie tussen die R563Q 
mutasie en pre-eklampsie uitkomste kon aangetoon word nie. Verdere navorsing 
gerig op pasiënte met chroniese hipertensie of akute, onstabiele pre-eklampsie in 
groter studiegroepe kan die verband tussen die mutasie en die pre-eklampsie 
fenotipe moontlik beter toelig. 
 
 7 
Acknowledgements 
 
Dr GS Gebhardt for making the sample bank available for use in this study. 
 
Sr E Van Papendorp for help with accessing data for the patients. 
 
Dr R Hillerman and colleagues for the genetic analysis. 
 
Prof DW Steyn for assistance with statistical calculations. 
 
 8 
Table of Contents 
 page 
Declaration 2 
  
Abstract & Opsomming 3 
  
Acknowledgements 7 
  
List of Figures  9 
  
List of Tables 10 
  
List of Addendums 12 
  
Chapter 1  - Literature review  
1.1.  Introduction 
1.1.1 Implication of ENaC in hypertension 
1.1.2 Pre-eclampsia and and ENaC 
1.2   The molecular biology of pre-eclampsia 
1.3   Overview of recent articles relevant to this study 
1.4   Aims of index study 
13 
 
16 
20 
22 
  
Chapter 2 - Methods 23 
  
Chapter 3 - Results 26 
  
Chapter 4 - Discussion 33 
  
Conclusion 38 
  
References 39 
  
Appendix 42 
 9 
List of Figures 
Figure page 
  
1. Electrophoresis specimen: genotyping 25 
  
2. Electrophoresis specimen: unsuccessful DNA extraction 25 
  
3. Combined odds ratio:   All patients 
35 
  
4. Combined odds ratio:   Black patients 
35 
  
5. Combined odds ratio:   Mixed ancestry patients 
35 
  
 10 
List of Tables 
Table page 
  
1.     Noteworthy family clustering studies of pre-eclampsia 17 
  
2.     Summary of the most commonly researched genes     
        for association with pre-eclampsia 
19 
  
3.     Summary of Rayner study findings7 21 
  
4.     Summary of Dhanjal study findings9 22 
  
5.     The age differences between the study and control groups 26 
  
6.     Prevalence of the mutation: study patients v controls 26 
  
7.     Racial differentiation 25 
  
8.     Severity of the hypertensive disorder 27 
  
9.     Placental function according to Doppler 28 
  
10.   Prevalence of abruptio placentae 28 
  
11.   Gestational age at delivery 28 
  
12.   Route of delivery 29 
  
13.   Pregnancy outcomes 29 
  
14.   Weight for gestational age 30 
  
15.   Birth weight distribution 30 
  
16.   Apgar at 5 minutes 31 
  
17.   Apgar at 10 minutes 31 
 11 
 
Table page 
  
18.   NICU admission  31 
  
19.   Neonatal complications 32 
  
20.   Composite outcome comparison 32 
  
21.   Breakdown of composite outcome 32 
  
22.   Comparable data (Index study v Dhanjal et al 9) 34 
  
23.   Combined data 34 
  
 12 
List of Addendums 
Addendum page 
  
A.  Consent form for participation in genetic hypertension research  40 
  
B.  Data capture form 41 
  
 
 13 
Chapter 1 - Literature review  
1.1    Introduction 
 
Hypertensive disease is one of the cardinal causes of maternal morbidity and 
mortality in South Africa. According to the National Confidential Enquiry into Maternal 
Deaths (NCEMD) report for 2005-2007, the “big five” causes of maternal death have 
remained the same as in the previous triennium, namely non-pregnancy related 
infections – mainly AIDS (43.7%), complications of hypertension (15.7%), obstetric 
haemorrhage (12.4%), pregnancy-related sepsis (9.0%) and pre-existing maternal 
disease (6.0%).1 Women under 20 years of age were at greater risk of dying due to 
complications of hypertension; women 35 years and older were at greater risk of 
dying of obstetric haemorrhage, ectopic pregnancies, embolism, acute collapse and 
pre-existing medical disease. Thus, as the second foremost cause of maternal death 
and the foremost direct obstetric cause of maternal death, the early identification and 
treatment of hypertensive disease remains important priorities in improving maternal 
care. Fortunately, from the latest NCEMD report there has been a significant 
decrease in the institutional Maternal Mortality Rate (14%) for complications of 
hypertension in pregnancy. The reason for this reduction, however, is unclear. 
 
Various blood tests have been suggested to identify women at risk of pre-eclampsia, 
including hCG, plasma fibronectin, increased circulating free fatty acids, 
hyperlipidemia, and markers of platelet activation.2 Several genetic studies have 
been undertaken and will be elaborated upon in the text. It is also well known that 
chronic hypertension is one of the major predisposing factors to the development 
pre-eclampsia.2 A continued search for a genetic screening test to assist in 
anticipating which women might be at higher risk for developing hypertensive 
disease holds the potential to impact positively on the reduction of maternal morbidity 
and mortality. 
 
The aim of this project is to determine the prevalence of the R563Q mutation of the 
-subunit of the epithelial sodium channel ( -ENaC) gene in a cohort of primigravid 
women with hypertensive disease in pregnancy and to compare pregnancy 
outcomes in this group of hypertensive patients with those not identified to be 
carriers of the mutation. 
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1.1.1 Implication of the epithelial sodium channel (ENaC) in 
hypertension 
 
The body’s sodium balance is a critical factor in blood pressure regulation. The 
kidney acts as a central regulator of sodium homeostasis by controlling renal salt 
handling by means of the renin-angiotensin system. Aldosterone is the primary 
hormonal effector in this system. Its principal effect is to stimulate sodium (Na+) 
absorption in the distal renal tubules and distal colon.3 
 
The epithelial sodium channel (ENaC) is a membrane bound protein consisting of 
three homologous sub-units ( ,  and ). These components are situated in the 
apical membrane of epithelial cells of the distal nephron. ENaC forms the controlling 
mechanism for sodium re-absorption in epithelial cells that line the distal nephron, 
distal colon, ducts of several exocrine glands and lung airways. The three ENaC 
subunits have been demonstrated in the renal epithelial cells of the distal convoluted 
tubule, connecting tubule, cortical collecting tubule and collecting duct, as well as in 
the medullary collecting duct. The sodium-potassium-ATP-ase (Na,K-ATPase) on the 
basolateral side of the cells provide the driving force for transepithelial Na+ transport. 
Aldosterone has been shown to strongly affect the ENaC. Upon stimulation, 
aldosterone binds to the intracellular mineralocorticoid receptor (MR). The active 
hormone-receptor complex interacts with hormone responsive elements in gene 
promoter areas, e.g. the 2 sub-unit of the Na,K-ATPase and modulates 
transcription. An increase in epithelial Na+ absorption is achieved by directly or 
indirectly activating promoter genes via aldosterone induced proteins. Thus, highly 
selective aldosterone-dependent epithelial sodium channels (ENaC) mediate Na+ 
transport in the distal nephron.4 
 
Genetic studies have made several attempts to prove that ENaC mutations result in 
hypertensive disease. Significant linkage was found between systolic blood pressure 
and micro-satellite markers on chromosome16p12. This region contains the genes 
that encode for the - and -ENaC subunits.5 Molecular analysis of two well 
described human genetic diseases, Liddle’s syndrome and 
pseudohypoaldosteronism type 1 (PHA-1), provided further direct evidence that 
ENaC dysfunction influences blood pressure.3 
Liddle’s syndrome is characterised by increased sodium transport despite low 
aldosterone levels.  Clinical presentation is hypertension with low plasma levels of 
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renin and aldosterone, and hypokalemia in some cases.  In PHA-1 there is 
decreased sodium absorption despite high levels of aldosterone. In both of these 
conditions, mutations in the ENaC subunits were demonstrated. In Liddle’s syndrome 
there are several activating mutations of the - and  sub-units, leading to constitutive 
re-absorption of Na+ and subsequent low levels of renin and aldosterone. In PHA-1, 
all three subunits ( ,  and ) are affected and hypofunction of the ENaC ensues with 
urinary salt wasting. 
 
Different mutations of ENaC were linked to other forms of hypertension: the T594M 
polymorphism and the R563Q mutation. The T594M variant, a polymorphism that is 
highly prevalent in black population groups, was linked to hypertension in a British 
study.6 The R563Q mutation was linked to low-renin, low-aldosterone hypertension.7 
This group also found that only a minority of the patients with R563Q allele fully 
express the Liddle’s syndrome phenotype. 
 
 
1.1.2    Pre-eclampsia and the ENaC 
 
In renal principal epithelial cells, mineralocorticoid receptor (MR) activation leads to 
an enhanced activity of ENaC and Na+ /K+ -ATPase. ENaC, with its three different 
subunits, seems to be differentially regulated in response to mineralocorticoids and 
glucocorticoids in different target tissues. It is described that (MR) mutations can 
cause severe pregnancy–induced hypertension, as a result of aldosterone mediated 
receptor activation through the 100-fold increased progesterone levels in pregnancy.8 
Hypertension is caused by gain-of-function mutation in the mineralocorticoid 
receptor, the mediator of aldosterone-induced sodium transport in the distal nephron, 
has been described, with the notable finding being that pregnancy causes a severe 
worsening of blood pressure. This finding stimulated further interest in the possible 
role for renin-angiotensin-aldoserone system abnormalities in the disease process of 
pre-eclampsia. 
 
In South Africa, epidemiologic information indicate that black women are prone to 
developing severe pre-eclampsia and suffering the consequences, with high 
maternal mortality and morbidity.9 The question arose whether a gene mutation could 
explain this association. The T594M variant of the -ENaC, which has been shown to 
be highly prevalent in black population groups, has been associated with 
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hypertension in a London population.6 This was however not confirmed in a South 
African study.10 In 2006 however, the R5630 -ENaC mutation was linked to pre-
eclampsia in black and mixed ancestry individuals in South Africa.9 
 
 
 
1.2 The molecular biology and genetics of pre-eclampsia 
 
A brief outline 
 
Pre-eclampsia is a multi-system pregnancy disorder characterised by hypertension 
and proteinuria on the grounds of diffuse endothelial dysfunction. It has a complex 
etiology and is not yet clearly understood. Etiological factors include maternal and 
fetal genetics and environmental factors.  
 
A clue to a genetic background for pre-eclampsia is that pre-eclampsia tends to 
cluster in families (Table 1).11 Data from an unpublished Utah genealogy database, 
showed that the incidence of pre-eclampsia was higher in families: more than 30 
standard deviations separated the occurrence in the control group. The risk for pre-
eclampsia in the female offspring of a pre-eclamptic mother was 20-40% and for 
siblings of the index case 11-37%.11 Much lower rates are seen in non-blood 
relatives. African American mothers have a higher rate of pre-eclampsia, at all socio-
economic levels, suggesting that ethnicity, more than socio-economic status, is the 
predisposing factor12. Twin studies shows the heritability of pre-eclampsia to be 
between 22-47 %.11,13  
 
The pathology underlying pre-eclampsia and the complex maternal-fetal interaction 
resulting in placental malfunction and the multi-system maternal syndrome may 
involve a multitude of ligands, receptors, amplification cascades and programmed 
responses on both the maternal and fetal sides. Any number of genetic disorders 
could affect the processes in the maternal endothelium or affect trophoblast 
physiology.11 
 
Table 1. Noteworthy family clustering studies of pre-eclampsia. 
Adapted form Chesley’s Hypertensive disorders
11
 
Author Year Area of study 
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Humphries 1960 Mother-daughter pairs 
Adams and Thompson 1961 Disease of pre-eclampsia, sisters of pre-eclamptics 
Chesley et al. 1968 
Pregnancies of daughters and grandmothers of eclamptics 
compared to daughters and daughters ‘’in-law’’ 
Cooper and Liston 1979 ‘’Severe’’ pre-eclampsia 
Sutherland et al 1981 
Increased preeclampsia in mothers and daughters of 
preeclamptics 
Agrimson et al 1990 
Increased rate of preeclampsia in mothers and daughters of 
preeclamptics 
Alexander  2007 Mother-fetus pairs, including male transmission 
 
In the search to unravel the etiology of pre-eclampsia, a large number of genetic 
studies have been performed, mostly focussing on maternal genes.14 The full list of 
candidate genes for pre-eclampsia is extensive. Susceptibility to the maternal and 
fetal features of the condition are probably conferred by different genes.15 Genetic 
research over the last decade indicate that, although some common genetic variants 
play an epidemiologic role in pre-eclampsia, the genetic contribution is much more 
complex, with non-Mendelian transmission, gene interaction, numerous variants and 
interaction with environmental factors in concert.11 Although there is interesting data 
linking pre-eclampsia with genes encoding the hereditary thrombophilias, HLA-G and 
the renin-angiotensin system, the studies were not all consistent for the specific 
candidate genes or loci.  
 
Genetic search strategies may include use of family studies, sib-pairs or twin studies, 
segregation analysis, linkage analysis, population association studies or studies of 
affected pedigree members of rare pedigrees, where inheritance of the condition 
appears to follow a Mendelian pattern.14 Maturity onset diabetes of the young 
(MODY), glucokinase receptor mutations14, Liddle’s syndrome and the ENaC 
mutation, as discussed above, serves as examples of apparently Mendelian 
inheritance of genetic susceptibility to complex disorders. 
Besides from ENaC mutations (including R563Q and T594M), candidate gene 
studies pertaining to the renin-angiotensin-aldosterone (RAA) system, and its linkage 
to pre-eclampsia, were the following: 
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 RFLP in the maternal renin gene in Icelandic pedigrees with more than three 
affected women was not associated with pre-eclampsia.16 
 
 T235 variant of the maternal angiotensinogen gene was linked to pre-
eclampsia in a US17 and Scottish/Icelandic population, but not in a similar UK 
study.18 
 
 Maternal-fetal angiotensinogen gene allele sharing was associated in pre-
eclampsia.19 
 
 ACE and ATII type 1 receptor has been demonstrated in spiral arteries. The 
hypothesis is that genetic variants may promote abnormal remodelling and 
predispose to pre-eclampsia.20 
 
 Decidual angiotensin expression was found to differ between alleles in a 
comparative study (T235 vs M235). These findings indicate the possible role 
of the fetal genotype in the RAA system in the etiology of pre-eclampsia.21 
 
 ATII receptors type 1 and 2, mediated by AGTR1 and AGTR2 genes 
mediates vasoconstriction, cellular growth, remodelling and apoptosis.23 Two 
AGTR1 alleles were found to be transmitted preferentially from the mother to 
the fetus in pre-eclampsia.22 A specific AGTR2 haplotype was also found 
more frequently in women with pre-eclampsia.24 
 
Other candidate gene studies in the hereditary thrombophilia area examined 
mutations in the MTHFR gene and factor V Leiden gene. Results were inconsistent.14 
Further genetic studies focussed on human leucocyte antigen that is expressed in 
the trophoblast at the placental decidual zone (HLA-G), nitric oxide synthetase gene, 
tumour necrosis factor-alpha and HADHA. For the last mentioned gene mutation, the 
result is long chain hydroxyl-acyl coenzyme-A dehydrogenase (LCHAD) deficiency. 
Certain susceptibility loci have been located by genome–wide scans. Results 
however were not conclusive and future large detailed studies are needed with 
maternal and fetal samples.14 Table 2 summarises of the most commonly studied 
genes.11 
 
 
Table 2. Summary of  most commonly researched genes for association with 
pre-eclampsia. 
Adapted from Chesley’s Hypertensive disorders
11
 
Chromosome 
location 
Gene 
Primary 
Polymorphism 
Studied 
Number 
of 
studies 
Presumed 
Biological 
Association with 
Pre-eclampsia 
Cumulative Evidence of 
Association 
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Other recent molecular studies relevant to the etiology of pre-eclampsia include 
detection of cell-free fetal DNA in maternal circulation and soluble fms-like thyrosine 
kinase (sFlt-1). Cell free fetal DNA have been shown to be elevated in pre-eclampsia 
and further elevated in HELLP syndrome. The raised levels may even be present 
before the onset of pre-eclampsia and may possibly offer predictive value.14 The 
elevation of sFlt-1 in the pre-eclamptic placenta is thought to be related to placental 
hypoxia. The sFlt-1 binds to vascular endothelial growth factor (VEGF) and deprives 
maternal endothelium of a vital growth factor, thus resulting in the maternal 
manifestation of dysfunctional endothelium.24 Elevated sFlt-1 is thus a marker for the 
early detection of the inflammatory pre-eclamptic process resulting form placental 
stress, rather than a direct etiological factor. 
 
Proteome analysis is a further research area to briefly mention. In a recent study 
published in Placenta, the analysis of 5 pre-eclamptic placentas (compared to 5 
normal placentas) indicated that there was down-regulation of proteins with 
antioxidant properties in pre-eclamptic placentas.25 
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1.3 Overview of recent articles relevant to this study 
 
 
1.3.1 Rayner study findings7 
 
This study, conducted in 2003 looked at the relationship between -ENaC mutation 
and low renin, low aldosterone hypertension. They found a new mutation of the -
ENaC, R568Q, and could strongly link it to this form of hypertension in their cohort of 
black and mixed ancestry South African patients. 
 
The new R563Q mutation was found in 10 of 139 hypertensive patients but in none 
of the normotensive patients (p=0.0058). The clinical and laboratory results of this 
study is summarised in Table 3. The frequency of the mutation in the subgroup of 14 
black patients with low renin low aldosterone hypertension was significanty greater 
(p=0.0001) than in normotensives, and was also greater (p=0.041) than in normal-
high renin hypertensives. This suggests that R563Q is an activating mutation. R563Q 
was also found in seven out of 250 mixed ancestry patients and was significantly 
(p=0.017) associated with low-renin, low aldosterone hypertension. The mutation 
was found in only one of 100 mixed ancestry normotensives, but not in any of the 
136 white hypertensives. Eleven of the 18 R563Q patients had severe hypertension, 
with 2 cases suffering renal failure. Only two had hypokalemia. Thus the minority of 
the affected patients displays the full Liddle’s syndrome phenotype. 
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Table 3.  Results of clinical and laboratory findings of Rayner at al, 2003
7
 
 R563Q positive R563Q negative 
Age (years, mean ± SD) 52.7±14.1    (n=18)* 47.1±15.6     (n=172) 
Sex 11males, 7 females 67 males, 105 females 
Population group 10 black, 8 mixed ancestry 53 black, 105 mixed ancestry, 
13 white 
Serum K+(mmol/l, mean±SEM) 
4.0±0.2    (n=14)* 4.2±0.04 (n=151) 
PRA**(ngml per h, mean±SEM) 
<0.1;0.2     (n=2) 2.8±0.8   (n=47) 
Plasma active renin 
(mU/l,mean±SEM) 
22.7±7.5  (n=11)* 61.7±8.9 (n=125) 
Plasma aldosterone 
(pmol/l, mean±SEM) 
172±18.2 (n=14)** 410±20   (n=172) 
*not significantly different from R563Q negative patients 
**Significantly different from R563Q negative patients; p<0.0001, Mann-Whitney test 
PRA=plasma renin activity, normal range 1-8ng/ml per h. Plasma active renin normal range 7-77mU/l.  
Plasma aldosterone normal range 190-970pmol/l. 
 
 
 
1.3.2 Dhanjal study findings9 
 
The frequency of the R563Q mutation in black and mixed ancestry (MA) patients with 
pre-eclampsia was compared to that in normotensive, ethnic matched controls. Data 
from 412 women were obtained, of which 192 normotensive women and 230 women 
with pre-eclampsia. The significant differences in demographics included age, birth 
weight and gestation at delivery. Pre-eclamptic women were also older than controls, 
with smaller babies born at younger gestations. A total of 23 women were identified 
as mutation carriers. The frequency of pre-eclampsia (7.8%) was significantly higher 
amongst the mutation bearers than in the control group 2.6% (p=0.014). With 
subgroup analysis according to ethnicity, the frequency of the mutation was 
significantly higher in black women. In the MA group the mutation frequency was 
increased but not significantly so. The mean renin level was significantly lower in pre-
eclamptic mutation positive subjects while aldosterone and potassium levels were 
not different. These levels were however low in all groups compared to levels in 
white population groups. The comparative prevalence of the mutation in the study is 
summarised in Table 4.  
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Table 4. Prevalence of R563Q mutation in pre-eclamptics compared to controls
9
 
 Normotensive pregnant women Women with pre-eclampsia p-value 
All subjects n 192 230  
 age 25.7 6.0 27.6 6.8 0.0027* 
 mutation+ (%) 5 (2.6) 18(7.8) 
0 014** 
 mutation- 187 212 
Black mutation+ (%) 3(2.3) 12(8.1) 
0.031** 
 mutation- 124 136 
MA mutation+(%) 2 (3.1) 6(7.3) 
0.22** 
 mutation- 63 76 
* Student’s unpaired t-test (two tailed) 
**Fisher’s exact test (one sided) 
 
 
 
 
1.4 Aim of index study 
 
 
Following to the linkage of the R563Q allele to hypertension and pre-eclampsia in 
black and mixed ancestry patients in a South African cohort, the index study further 
explores the relationship between this specific genetic defect and pre-eclampsia. As 
little is known regarding the effect of the mutation on pre-eclampsia outcomes, a 
retrospective study cohort in an existing database of blood samples from pre-
eclamptic women were analyzed and correlated to the course and complications of 
their pregnancies. The group consisted of a cohort of primigravid patients with early 
onset pre-eclampsia. The allele frequency in this group was compared to that in a 
healthy control group. The pregnancy outcomes in subjects with and without the 
affected R563Q allele were compared.  
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Chapter 2 - Methods 
 
A retrospectively collected study cohort was used. The selected study population 
was primigravid patients with early onset pre-eclampsia.  The control group consisted 
of age matched women who had uncomplicated pregnancies. Pooled blood samples 
and data from the GAP study (Genetic Aspects of Pre-eclampsia, project number 
C99/025) were used for both the study group and the control group. Patients 
originated from the eastern Metropole of Cape Town and surrounding areas, 
including two regional referral hospitals (Paarl and Worcester) and rural areas of the 
Western Cape. 
 
The GAP study was conducted in Tygerberg Academic Hospital (a tertiary referral 
center) and focused on genetic associations (MTHFR, Factor V Leiden, Prothrombin 
and LDL) with pre-eclampsia. The initial phase of the GAP study was from 1998 to 
2001. The study recruited patients with early onset pre-eclampsia (primigravidae and 
multigravidae), pre-eclampsia beyond 34 weeks, intra-uterine growth restriction and 
abruptio placentae. A sample bank of maternal and fetal specimens was established 
that was subsequently used for further genetic studies. Recruitment resumed 
periodically for this purpose and concluded in September 2008. Patients were 
enlisted consecutively during recruitment periods and had to be able to give consent 
for participation in genetic research. (Addendum A) Data for each patient was 
captured and stored in a database by means of completion of a data collection sheet 
(Addendum B).  
 
The planned sample size was 400 - 200 study patients and 200 control patients. 
Sample size was determined assuming a polymorphism frequency of 5% in 
hypertensives and 0.1% in the normotensive controls. (  = 0.05,  = 0.20). Controls 
were ethnic-matched women who were normotensive during pregnancy and delivery. 
 
Included samples were specimens from primigravidas with early onset pre-eclampsia 
(33 weeks and under). Exclusion criteria were gestation 34 weeks and over, multiple 
pregnancy, patients known with underlying collagen vascular disease or type I 
Diabetes Mellitus. 
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Pre-eclampsia was defined as hypertension with onset after 20 weeks gestation 
(mild/moderate >140/90 mmHg, <160/110 mmHg, severe 160/110 mmHg) and 
proteinuria (2+ protein on side room urinalysis on 2 occasions, or 24h urine protein 
0.3g). Outcome criteria were the severity of the hypertensive disorder, (severe pre-
eclampsia, mild-moderate pre-eclampsia or eclampsia) placental function (according 
to Doppler studies of the resistance index in the umbilical artery), the presence of 
abruptio placentae, delivery (gestational age, route of delivery, reason for delivery), 
maternal complications (HELLP syndrome, pulmonary oedema, renal compromise or 
other) and neonatal outcome (intrauterine death, termination before viability, low birth 
weight and small for gestational age, Apgar score, admission to neonatal intensive 
care, hospital stay and neonatal complications). Estimation of weight for age for was 
performed using a centile charts for birth weight for the local urban population of the 
Western Cape.26,27  
 
In the laboratory, DNA extraction and purification was performed by the overnight salt 
extraction method, followed by PCR amplification with designated primers. Overnight 
digestion of the resulting product was allowed. The restriction enzyme was Sfc1.  
Analysis of the product was achieved by gel electrophoresis (4% agarose gel). 
Results were stained with ethidium bromide and visualised under UV light. An 
example of the electrophoresis strips is displayed in Figure 1.  
 
On the marker strip as illustrated in Figure 1, The GG type is the normal form of the 
genotype. The GA type is the mutant heterozygous form and the AA type the mutant 
homozygous form. In some of the DNA samples, analysis was unsuccessful (Fig. 2). 
 
Statistical processing of categorical data was done using the Chi2 test with Yates 
correction. For categories with expected values of less than 5, the two-tailed Fisher’s 
exact test was used. Means of normally distributed data were compared with the 
Student’s t-test. Medians of data with an abnormal distribution were compared with 
the Mann-Whitney U-test. Comparable data from the previous study by Dhanjal et al9 
was combined with that of the index study and combined odds ratios and 95% 
confidence intervals were calculated using Revman 4.2 software. 
 
The laboratory specimens and data sheets did not contain information of the patient’s 
name and file number to allow identification of individuals. Permission for the project 
was obtained from the Tygerberg Ethics Committee (Project number N07/07/163).
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Fig.1 Electrophoresis specimen: genotyping 
 
 
 
 
Fig. 2 Electrophoresis specimen: unsuccessful DNA extraction 
 
 
Genotyping was performed in the laboratory of Dr Renate Hillermann, Department of 
Genetics, University of Stellenbosch.  Costs for this project (Primers and restriction 
enzyme, PCR amplification and gel electrophoresis) were covered by existing funds. 
GG type GA type AA type 
Unsuccessful extraction 
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Chapter 3 - Results 
 
Of the 200 planned patients, 104 samples were analysed. Of the 200 planned 
controls, 80 samples were analysed. The mean age was 21.7( 4.6) in the study 
group compared to 27.7( 7.1) in the control group as in Table 5. 
 
Table 5.  The age differences between the study and control groups 
 
Normotensive pregnant 
women 
Women with pre-
eclampsia 
p-value 
All subjects n 80 104 
p < 0.0001* 
 age (SD) 27.7 ( 7.1) 21.7 ( 4.6) 
*Mann-Whitney U-test 
 
 
The mutation was identified in heterozygous form in 12 (11.5%) of the 104 study 
patients. Of the 80 normal control patients, 5 (6.3%) had the mutation, of which 4 in 
the heterozygous form and one in the homozygous form of the gene mutation. None 
of the pre-eclamptic study patients had the mutation in homozygous form (p = 0.33) 
as illustrated in Table 6. 
 
 
In the study group, the racial distribution in the mutation negative group was 35 
blacks, 53 of mixed ancestry (MA) and 4 whites. The mutation positive group was 
comprised of 5 blacks and 7 MA patients. In the control group, the mutation negative 
group was comprised of 9 blacks and 66 MA patients, while the mutation positive 
group was comprised of 0 blacks and 5 MA patients. There were no whites in the 
control group. No difference was demonstrated in mutation frequency in the black 
subgroup (p = 0.57) or the MA subgroup (p = 0.56) as shown in Table 7.  
Table 6. Prevalence of the mutation (homozygous + heterozygous) 
OUTCOME Mutation + Mutation -  p-value 
Genotype  
n= 104 Patients  12  (11.5%) 92 OR = 1.96 (95%CI 0.66 - 5.80) 
p = 0.33* n = 80 Controls  5    (6.3%) 75 
*   Chi squared test, Yates corrected p-value 
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For statistical analysis, the groups grading the severity of the hypertensive disorder 
were combined. The patients with severe pre-eclampsia and eclampsia were 
combined in one group (severe) and patients with mild-moderate disease in the other 
group (Table 8).  For hypertensive disease as an outcome the variables were as 
follows: 8 of the 12 mutation bearers had severe pre-eclampsia disease, 2 had 
mild/moderate disease and 2 had eclampsia. Among the mutation negative group 
(n=92), 26 (28.3%) had mild-moderate pre-eclampsia, 62 (67,0%) severe pre-
eclampsia and 4 had eclampsia (p=0.018). 
 
 
Doppler studies of the umbilical artery resistance index were normal in 60 of the 
mutation negative group and 6 of the mutation positive group. Abnormal Dopplers 
(above the 95th percentile (>P95), absent end diastolic flow (AEDF) and reversed end 
diastolic flow (REDF)) were grouped together for the statistical analysis. In the 
mutation negative group, 18 patients had abnormal Dopplers (>P95 8, AEDF 8, 
REDF 2) and in the mutation positive group 2 patients had abnormal Dopplers (>P95 
1, REDF 1). Doppler studies were not done in 13 mutation negative patients and 4 
mutation positive patients (Table 9). 
 
Table 7. Racial differentiation 
PREVALENCE Mutation + Mutation -  p-value 
Racial  
Black Study population 5 35 
p = 0.57* 
 Controls 0 9 
MA Study population 7 53 OR = 1.74 (95% CI 0.46-6.78)** 
p = 0.54  Controls 5 66 
White Study population 0 4 
 
 Controls 0 0 
* Fisher’s exact test (two tailed) 
** Chi squared test with Yates correction 
Table 8.   Severity of the hypertensive disorder 
OUTCOME Mutation + Mutation - p-value 
Severity of pre-eclampsia  
n = 76 Severe  10 66 
p=0.51 
n = 28 Mild-moderate  2 26 
* Fisher’s exact test (two tailed) 
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Abruptio placentae (Table 10) occurred in 6 mutation negative patients and in none 
of the mutation positive group (p=1.00). 
 
 
Gestational age at delivery for the mutation negative group was divided in births 
<28weeks (17 patients), between 28-33weeks (57 patients) and 34 weeks and 
beyond (18 patients). For the mutation positive group, 3 patients delivered before 28 
weeks, 8 patients between 28 and 33 weeks and 1 patient at 34 weeks, (p=0.690). 
Gestational age at delivery data was then combined in the group below 34 weeks 
and 34 weeks and beyond for statistical analysis (Table 11). 
 
 
The route of delivery was known in 91 of the mutation negative patients, of whom 24 
(26,3%) had normal vaginal delivery and all others were operative deliveries (Table 
12). Indication for the operative deliveries were fetal distress in 43 (64,2%) of 
patients, failed induction of labour (6) elective (4) for fetal indication (1) hysterotomy 
(2) and unknown indication (11).  Route of delivery was known in all of the mutation 
bearers. Out of the 12 patients, 4 delivered normally and 8 had caesarean sections 
Table 9.  Placental function according to Doppler 
OUTCOME Mutation + Mutation -  p-value 
Placental function according to Doppler  
n = 66 Normal 6 60 
p = 1.00* 
n = 21 Abnormal 2 19 
* Fisher’s exact test (two tailed) 
Table 10. Prevalence of abruptio placentae 
OUTCOME Mutation + (n=12) Mutation –  (n=92) p-value 
Abruptio placentae  
n = 6 Present 0 6 
p = 1.00* 
n = 98 Absent 12 86 
* Fisher’s exact test (two tailed) 
Table 11.  Gestational age at delivery 
OUTCOME Mutation + Mutation - p-value 
Gestation at delivery  
n = 85 <  34 w 11 74 
p = 0.69* 
n = 19  34w 1 18 
* Fisher’s exact test (two tailed) 
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of which 4 for fetal distress, 3 for failed induction and 1 for unknown indication 
(p=0.74). There was insufficient information on the reason for induction of labour or 
delivery by caesarean section in both groups of patients. 
 
 
Maternal complications were recorded in the database. In the mutation negative 
group, 6 patients developed HELLP syndrome and 9 had ascites. In the mutation 
positive group, 1 patient had HELLP syndrome and 1 had ascites. 
 
The pregnancy outcomes for the mutation negative group were divided into live 
births, 68 (73.9%), early neonatal losses, 8 (8.7%), stillbirths, 4 (4,3%), and 
termination before viability, 12 (13.0%). The mutation positive group had 9 live births, 
no early neonatal losses, 1 stillbirth and 2 terminations before viability. Combining 
the outcomes into live babies versus pregnancy losses (Table 13), the mutation 
negative group had 68 (73.9%) live births and 24 (26.1%) had losses. The mutation 
positive group had 9 live births and 3 losses (p=1.00). 
 
 
The birth weight distribution ( 24weeks, n=91) was determined according to local 
centile graphs.26,27 In the mutation negative group: under the 10th centile (<P10) 35 
(38.5%), between the 10th and 50th centile 35 (38.5%), more than or equal to the 50th 
centile ( P50) 21 (23.0%). In the mutation positive group ( 24weeks, n=10) there 
were 3 babies <P10, 5 babies between the 10th and 50th centile and 2 babies P50. 
The groups were then combined to form 2 categories, <10th centile and above or 
equal to the 10th centile ( P10) (Table 14). The mutation negative group had 35 
Table 12.  Route of delivery 
OUTCOME Mutation+ Mutation -  p-value 
Route of delivery  
n = 75 Operative delivery 8 67 
p = 0.73* 
n = 28 Normal birth 4 24 
* Fisher’s exact test (two tailed) 
Table 13.   Pregnancy outcomes 
OUTCOME Mutation + Mutation - p-value 
Pregnancy outcome  
n = 27 Perinatal loss 3 24 (26.1%) 
p = 1.00* 
n = 77 Alive 9 68 (73.9%) 
* Fisher’s exact test (two tailed) 
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(38.5%) babies <10th centile and 56 (61.5%) P10 centile. The mutation positive 
group had 3 babies below the 10th centile and 7 babies P10 (p=0.74). 
 
 
 
In the mutation negative group the birth weight distribution was as follows: 26 babies 
<1000g, 45 babies between 1000 -1800g, 37 babies 1800g. The mutation positive 
patients had 4 babies <1000g, 7 babies 1000-1800g and 1 baby 1800g. The weight 
categories were then combined (Table 15): In the group <1500g, mutation negative 
patients had 55 (59.8%) babies and mutation positive patients had 10 babies. In the 
group 1500g the mutation negative group had 37 (40.2%) babies and the mutation 
positive group had 2 babies (p=0.20). 
 
 
 
In the mutation negative group, 76 babies were born alive. The available Apgar 
scores in the mutation negative group (n = 74):  at 5 minutes 18 babies had an Apgar 
score <8 (24.3%), of which only 2 were under 4; 56 babies had an Apgar score 8 
(75.7%), 3 scores were unknown and 15 not applicable because of stillbirth or non-
viable termination (Table 16).  At 10 minutes (n = 76) only 3 were <8 (of which none 
were <4) and 73 were 8. Apgar score was unknown in 10 patients and not 
applicable in 6 cases.  In the mutation positive group, at 5 minutes, 2 were <8 (of 
which none were <4) and 7 were 8 (p=1.00). In three cases Apgar scores were not 
applicable. At 10 minutes, 9 were 8 and 3 were not applicable (Table 17). Babies 
with 5 minute Apgar scores less than 8 were compared with those with Apgar scores 
Table. 14.  Weight for gestational age 
OUTCOME Mutation + Mutation– p-value 
Weight for gestational age  
n = 38 <  P10 3 35 (38.5%) 
p =  0.74* 
n = 63   P10 7 56 (61.5%) 
* Fisher’s exact test (two tailed) 
Table15.  Birth weight distribution 
OUTCOME Mutation + (n=12) Mutation–   (n=92) p-value 
Birth weight in grams  
<  1500g 10 55 (59.8%) 
p = 0.20* 
 1500g 2 37 (40.2%) 
* Fisher’s exact test (two tailed) 
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of 8 or more (Table 16.) Similarly, the 10 minute Apgar scores were compared (Table 
17).  
 
 
 
 
Of the mutation negative group (Table 18), 13 babies were admitted to the neonatal 
intensive care (NICU). Sixty babies did not require admission. For 18 births, NICU 
was not relevant (intrauterine death, non-viable termination or pre-NICU demise). In 
one case information was lacking. In the mutation positive group one baby was 
admitted to NICU. Eight babies did not require NICU and in 3 cases NICU was not 
relevant (intrauterine death, non-viable termination or pre-NICU demise).   There was 
not enough information in the database about the length of stay in the NICU. 
 
 
Neonatal complications in the mutation negative group (Table 19) included 
prematurity 45, respiratory distress syndrome 11, necrotising enterocolitis 2, sepsis 
6, early neonatal demise 8, and unknown complications 3; some babies suffered 
more than one complication. The number of babies in the mutation negative group 
Table 16.  Apgar at 5 minutes 
OUTCOME Mutation + (n=9) Mutation – (n=74) p-value 
Apgar at 5 min  
Apgar  < 8 2 18 
p = 1.00* 
Apgar  8 7 56 
* Fisher’s exact test (two tailed) 
Table 17.  Apgar at 10 minutes 
OUTCOME Mutation + (n=9) Mutation – (n=76) p-value 
Apgar at 10min  
Apgar  < 8 0 3 
p = 1.00* 
Apgar  8 9 73 
* Fisher’s exact test (two tailed) 
Table 18.  NICU admission 
OUTCOME Mutation + (n=9) Mutation – (n=73) p-value 
NICU admission  
Yes 1 13 
 p = 1.00* 
No 8 60 
* Fisher’s exact test (two tailed) 
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with complications was 46, with no complication in 27 babies. In the mutation positive 
group, the complication in 6 babies was prematurity, including respiratory distress; 3 
babies had no complications. 
 
A composite outcome was created, combining all adverse outcomes of pre-
eclampsia (maternal and fetal) and a comparison was made between the mutation 
positive and negative groups (Table 20). The composite outcome ( 1 adverse event) 
was present in all the mutation bearers and in 89 of the mutation negative group. A 
further breakdown of the composite outcome is given in table 21. 
 
Chapter 4 - Discussion 
 
 
The study was conducted in an attempt to gain insight into the effect of the R563Q 
mutation on the outcomes of pre-eclampsia. The study findings do not point to a 
Table 19. 
  
Neonatal complications 
OUTCOME Mutation + (n = 9) Mutation – (n = 73) p-value 
Complications  
Premarurity and related complications) 6 46 
p = 1.00* 
No complications 3 27 
*  Fisher’s exact test (two tailed) 
Table 20.  Composite outcome comparison 
OUTCOME Mutation +    (n=12) Mutation –   (n=92) p-value 
Composite adverse  outcome  
Present ( 1 adverse outcome) 12 89 
p = 1.00* 
No adverse outcome 0 3 
*  Fisher’s exact test (two tailed) 
Table 21. Composite outcome  
OUTCOME Mutation +    (n=12) Mutation –   (n=92) 
Composite adverse  outcome   
None 0 3 
Any one 1 2 
Any 2 1 11 
Any 3 1 14 
Any 4 2 9 
Any 5 6 26 
>5 1 27 
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major relationship of pre-eclampsia, specifically of early onset with pre-eclampsia in 
primigravid patients, with the R563Q mutation, on the studied outcome measures. 
When extrapolating from the finding that mineralocorticoid receptor mutation 
phenotypes present with severe pregnancy induced hypertension9, the expected 
association was not demonstrated (Table 8).  The small sample size achieved in this 
study may have resulted in a Type II (β) error  (failing to reject the null hypothesis 
when the null hypothesis is false). The relation between the prevalence of the 
mutation amongst pre-eclamptics that was indeed previously statistically linked to 
hypertension and pre-eclampsia (discussed in the studies outlined in the literature 
review7,9) was not significant. No association was found between the mutation and 
the degree of pre-eclampsia in this study population (Table 8). A statistically 
significant finding was the significantly younger age of the pre-eclampsia patients 
compared to the control group patients (Table 5).  It is most likely a reflection of the 
known tendency for pre-eclampsia to occur more frequently in primigravidas, while 
the control group was ethnic matched women who had uncomplicated pregnancies 
and were likely multigravidas, who were chosen on the background of uncomplicated 
obstetric histories. 
 
The small numbers in the index study was due to technical problems with the sample 
bank, i.e. samples that were not successfully analysed (Fig. 2) as DNA could not be 
retrieved, along with a shortage of samples in the data bank. The sample size 
according to the initial power calculation of the study was not achieved.  
 
The data from the index study (Table 21) was combined with comparable data from 
the study by Dhanjal et al. that looked at the mutation frequency in pre-eclamptic 
populations (Table 22). Combined odds ratios (OR) were calculated (Fig. 3 to 5). A 
subgroup comparison was also performed (Tables 24 and 25), looking at the 
mutation frequency in the individual black and mixed ancestry (MA) subgroups. The 
prior study did not include any white patients and this subgroup could not be 
compared.  When combining all study patients, the association of pre-eclampsia with 
the R563Q mutation remains significant [OR 2.57 (95%CI 1.23-5.36)], as was found 
in the original trial. This association was also significant in the black subgroup [OR 
3.51 (95%CI  1.07-11.51)], but not in the MA subgroup [OR 1.99 (95%CI 0.76-5.23)].  
 
 
Table 22. Prevalence of R563Q mutation in pre-eclamptics compared to controls
 
– 
Index study data 
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 Normotensive pregnant women Women with pre-eclampsia P value 
All subjects n 80 104  
age 27.7 ( 7.1) 21.7 ( 4.6) p < 0.0001* 
mutation  + 5 12 
p = 0.33** 
mutation  - 75 92 
Black mutation +   0 5 
p = 0.57** 
mutation  - 9 35 
MA mutation  + 5 7 
p = 0.56*** 
mutation  - 66 53 
*     Mann-Whitney U-test 
**   Fisher’s exact test (two tailed) 
***  Chi squared test with Yates correction 
  
 
Table 23.  Combined data of Dhanjal et al. and Index study 
Subjects 
DHANJAL 
Controls* 
INDEX 
Controls* 
Combined 
Controls 
DHANJAL 
Study 
patients** 
INDEX    
Study 
patients** 
Combined 
study 
patients 
All n 192 80 272 230 104 334 
 age 25.7 27.7  27.6 21.7  
 mut+ ^ 5 5 10 18 12 30 
 mut -^^ 187 75 262 212 92 304 
Black mut + 3 0 3 12 5 17 
 mut - 124 9 133 136 35 171 
MA mut+ 2 5 7 6 7 13 
 mu - 63 66 129 76 53 129 
White mut + 0 0  0 0  
 mut- 0 0  0 4  
^       Mutation positive 
^^     Mutation negative 
*       Normotensive pregnant women 
**      Women with pre-eclampsia 
MA – Mixed Ancestry 
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Fig 3. Combined Odds Ratio: All 
patients 
Fig 4. Combined Odds Ratio: Black 
patients 
Fig 5. Combined Odds Ratio: Mixed Ancestry (MA) patients 
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When reviewing the outcome findings of the index study an interesting question 
arises: Would the findings change significantly should another study population be 
chosen?  
 
 Since it has been found that this ENaC mutation predisposes to hypertension 
independent of pregnancy, an additional population for future research could 
include patients with chronic hypertension.7 When examining chronic 
hypertensives in pregnancy, the development of superimposed pre-
eclapmpsia and outcomes could then be correlated to the presence of the 
mutation.   
 
 Acutely ill patients, who could not give consent, and post-partum patients 
were excluded form the databank, thus effectively including only stable pre-
eclamptics who qualified for expectant management. As MR defects (which 
activate ENaC) in pregnancy lead to severe pregnancy induced hypertension, 
this most likely warrants a further search into patients who present with 
complicated or unstable pre-eclampsia or who are emergently admitted to 
critical care units and thus not suitable for expectant management (i.e. 
pulmonary oedema, anuria with renal insufficiency, pre-hospital eclampsia, 
abruptio placentae).  
 
 
 From the combined data, the tendency towards pre-eclampsia in black 
individuals with the mutation seems significantly higher than in individuals of 
mixed ancestry. The index study population included a majority of mixed 
ancestry patients, which could serve to suggest that selecting an only black 
cohort of patients might be of more value in examining the R563Q gene 
defect in pre-eclampsia. The Dhanjal study group comprised of a majority of 
black patients, a selection that likely was more on target to retrieve significant 
study results. 
 
 
A further unexpected finding was the one control patient who exhibited the 
homozygous (AA) mutation genotype. It would be interesting to learn whether this 
patient developed hypertension in later life, however, the use of a retrospective, 
anonymous sample bank unfortunately limits elaboration on this point. 
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Although the association of the R563Q mutation with pre-eclampsia remains positive 
when looking at greater numbers, it is still not very strong, and it could not be 
significantly linked to specific adverse pregnancy outcomes. Other factors are likely 
to play a more significant role in the elusive etiology and phenotypic behaviour of 
pre-eclampsia. 
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Conclusion 
 
In this study the R563Q mutation of the ß-subunit of the epithelial sodium channel 
gene was not linked to pre-eclampsia. No significant negative correlation could be 
established between the presence of the R563Q mutation and the outcomes of pre-
eclampsia.  
 
When combining the mutation prevalence with the data from the prior study that did 
prove a statistically significant link, the association with the defect and pre-eclampsia 
remained significant. Further suggested research includes examining the R563Q 
mutation in chronic hypertensives in pregnancy and unstable pre-eclampsia and 
examining pre-eclampsia outcomes in larger study groups. 
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